While previous studies predominantly focused on propofol’s effects on tumor angiogenesis by modulating VEGF secretion from cancer cells, our findings demonstrate that propofol also acts directly on ECs in non-tumor contexts, expanding its pharmacological significance beyond anesthesia and tumor biology. The gene discussed is VEGFA; the disease is cancer.